Suppr超能文献

重新审视静脉治疗后肺部恶化的基础肺功能恢复情况。

Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.

机构信息

University of Washington School of Medicine, 1920 Terry Ave, Suite 400, Seattle, WA 98101, United States; CFF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, United States.

CFF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, United States.

出版信息

J Cyst Fibros. 2023 Sep;22(5):864-867. doi: 10.1016/j.jcf.2023.02.006. Epub 2023 Feb 16.

Abstract

CF registry pulmonary exacerbation (PEx) analyses have employed "before and after" spirometry recovery, where the best percent predicted forced expiratory volume in 1 s (ppFEV) prior to PEx ("baseline") is compared to the best ppFEV <3 months post-PEx. This methodology lacks comparators and ascribes recovery failure to PEx. Herein, we describe 2014 CF Foundation Patient Registry PEx analyses including a comparator: recovery around nonPEx events, birthdays. 49.6% of 7357 individuals with PEx achieved baseline ppFEV recovery while 36.6% of 14,141 achieved baseline recovery after birthdays; individuals with both PEx and birthdays were more likely to recover baseline after PEx than after birthdays (47% versus 34%); mean ppFEV declines were 0.3 (SD=9.3) and 3.1 (9.3), respectively. Post-event measure number had more effect on baseline recovery than did real ppFEV loss in simulations, suggesting that PEx recovery analyses lacking comparators are prone to artifact and poorly describe PEx contributions to disease progression.

摘要

CF 登记处的肺恶化(PEx)分析采用了“前后”肺活量恢复,其中将 PEx 前(“基线”)最佳预测百分比用力呼气量(ppFEV)与 PEx 后<3 个月的最佳 ppFEV 进行比较。这种方法缺乏对照,并将恢复失败归咎于 PEx。在此,我们描述了包括对照在内的 2014 年 CF 基金会患者登记处 PEx 分析:非 PEx 事件、生日的恢复。在 7357 名患有 PEx 的个体中,有 49.6%达到了基线 ppFEV 恢复,而在 14141 名个体中,有 36.6%在生日后达到了基线恢复;同时患有 PEx 和生日的个体在 PEx 后比生日后更有可能恢复基线(47%比 34%);平均 ppFEV 下降分别为 0.3(SD=9.3)和 3.1(9.3)。在模拟中,事件后测量次数对基线恢复的影响大于实际 ppFEV 损失,这表明缺乏对照的 PEx 恢复分析容易产生假象,并且无法很好地描述 PEx 对疾病进展的影响。

相似文献

1
Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
J Cyst Fibros. 2023 Sep;22(5):864-867. doi: 10.1016/j.jcf.2023.02.006. Epub 2023 Feb 16.
2
The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
J Cyst Fibros. 2021 Nov;20(6):932-936. doi: 10.1016/j.jcf.2021.02.012. Epub 2021 Mar 5.
3
Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
Pediatr Pulmonol. 2020 Mar;55(3):828-834. doi: 10.1002/ppul.24577. Epub 2019 Nov 20.
4
Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Ann Am Thorac Soc. 2023 Sep;20(9):1293-1298. doi: 10.1513/AnnalsATS.202301-078OC.
6
Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
Pediatr Pulmonol. 2017 Oct;52(10):1268-1275. doi: 10.1002/ppul.23765. Epub 2017 Sep 7.
7
Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.
J Cyst Fibros. 2021 Nov;20(6):926-931. doi: 10.1016/j.jcf.2021.02.001. Epub 2021 Feb 19.
8
Continuous glucose monitoring indices predict poor FEV recovery following cystic fibrosis pulmonary exacerbations.
J Cyst Fibros. 2021 Sep;20(5):785-791. doi: 10.1016/j.jcf.2021.03.004. Epub 2021 Mar 26.
9
Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Ann Am Thorac Soc. 2023 Jan;20(1):75-82. doi: 10.1513/AnnalsATS.202203-201OC.
10
Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations.
Pediatr Pulmonol. 2021 Jul;56(7):2036-2042. doi: 10.1002/ppul.25409. Epub 2021 Apr 20.

本文引用的文献

1
Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
Pediatr Pulmonol. 2020 Mar;55(3):828-834. doi: 10.1002/ppul.24577. Epub 2019 Nov 20.
2
Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
Pediatr Pulmonol. 2017 Oct;52(10):1268-1275. doi: 10.1002/ppul.23765. Epub 2017 Sep 7.
3
Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.
J Cyst Fibros. 2017 Sep;16(5):607-615. doi: 10.1016/j.jcf.2017.04.004. Epub 2017 Apr 21.
4
The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.
Ann Am Thorac Soc. 2016 Jul;13(7):1173-9. doi: 10.1513/AnnalsATS.201511-781OC.
5
Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients.
J Cyst Fibros. 2015 Nov;14(6):755-62. doi: 10.1016/j.jcf.2015.01.007. Epub 2015 Feb 14.
6
Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations.
Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27.
7
Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
Pediatr Pulmonol. 2011 Feb;46(2):184-92. doi: 10.1002/ppul.21350. Epub 2010 Oct 20.
8
Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.
Am J Respir Crit Care Med. 2010 Nov 1;182(9):1137-43. doi: 10.1164/rccm.201001-0057OC. Epub 2010 Jun 25.
9
Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
Am J Respir Crit Care Med. 2010 Sep 1;182(5):627-32. doi: 10.1164/rccm.200909-1421OC. Epub 2010 May 12.
10
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.
Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. doi: 10.1164/rccm.200812-1845PP. Epub 2009 Sep 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验